Opendata, web and dolomites

IMMUcan SIGNED

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUcan project word cloud

Explore the words cloud of the IMMUcan project. It provides you a very rough idea of what is the project "IMMUcan" about.

ethical    combination    iuml    saliva    stored    sops    centralized    perform    immune    volumes    biological    ve    majority    recruiting    reproducibility    expert    analyze    understand    samples    investigations    rationale    assembled    host    tissues    checkpoints    material    biobank    technologies    independent    database    failures    period    cytoff    neck    seq    head    relevance    cutting    clinical    peptidogenomics    stool    biomarker    cancers    generating    single    colorectal    pursue    rna    treatment    blood    accessibility    inhibitors    contractual    centers    cell    microbiome    breast    gastric    edge    trials    population    immucan    uniform    immuno    absence    sustainability    mobilize    academic    follow    immunoprofiling    workflow    proposes    oncology    plan    inclusive    data    lung    industry    running    patients    platform    proofed    ten    academia    na    functioning    utilizing    collection    human    tumour    quality    therapies    interaction    predictive    processed    framework    tumor    immunotherapy    tissue    start    types   

Project "IMMUcan" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL 

Organization address
address: Avenue E. Mounier 83
city: Brussels
postcode: 1200
website: www.eortc.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 34˙937˙500 €
 EC max contribution 17˙830˙000 € (51%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) coordinator 7˙246˙773.00
2    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 2˙749˙727.00
3    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 1˙712˙880.00
4    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 1˙460˙332.00
5    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 1˙323˙000.00
6    KING'S COLLEGE LONDON UK (LONDON) participant 765˙066.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 628˙320.00
8    UNIVERSITAT ZURICH CH (ZURICH) participant 573˙700.00
9    INSTITUT CURIE FR (PARIS) participant 410˙000.00
10    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 250˙000.00
11    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 190˙200.00
12    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 160˙000.00
13    LIGUE NATIONALE CONTRE LE CANCER FR (PARIS) participant 120˙000.00
14    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 100˙000.00
15    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) participant 100˙000.00
16    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 20˙000.00
17    INSTITUT JULES BORDET BE (BRUXELLES) participant 20˙000.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
20    DE DUVE INSTITUTE BE (BRUXELLES) participant 0.00
21    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
22    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
23    INSTITUT DE RECHERCHE PIERRE FABRESAS FR (BOULOGNE BILLANCOURT) participant 0.00
24    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
27    OWKIN FRANCE FR (PARIS) participant 0.00
28    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

WEB-RADR 2 (2018)

WEB-RADR 2

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More